

manufacture bulk controlled substance intermediates for sale to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and § 952(a) and determined that the registration of Penick Corporation to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Penick Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and § 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: August 21, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9-21536 Filed 9-4-09; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated June 3, 2009, and published in the **Federal Register** on June 9, 2009, (74 FR 27347), Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II:

| Drug | Schedule |
|--|----------|
| 1-(1-Phenylcyclohexyl)pyrrolidine (7458). | I |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470). | I |
| 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473). | I |
| 1-Methyl-4-phenyl-4-propionoxypiperidine (9661). | I |

| Drug | Schedule | Drug | Schedule |
|---|----------|---|----------|
| 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663). | I | Dimethylthiambutene (9619) | I |
| 2,5-Dimethoxy-4-(n-propylthiophenethylamine (7348). | I | Dimethyltryptamine (7435) | I |
| 2,5-Dimethoxy-4-ethylamphetamine (7399). | I | Dioxaphetyl butyrate (9621) | I |
| 2,5-Dimethoxyamphetamine (7396). | I | Dipipanone (9622) | I |
| 3,4,5-Trimethoxyamphetamine (7390). | I | Drötebanol (9335) | I |
| 3,4-Methylenedioxyamphetamine (7400). | I | Ethylmethylthiambutene (9623) | I |
| 3,4-Methylenedioxyamphetamine (7405). | I | Etonitazene (9624) | I |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404). | I | Etorphine except HCl (9056) | I |
| 3-Methylfentanyl (9813) | I | Etoxicidine (9625) | I |
| 3-Methylthiofentanyl (9833) | I | Fenethylamine (1503) | I |
| 4-Bromo-2,5-dimethoxyamphetamine (7391). | I | Furethidine (9626) | I |
| 4-Bromo-2,5-dimethoxyphenethylamine (7392). | I | Gamma Hydroxybutyric Acid (2010). | I |
| 4-Methyl-2,5-dimethoxyamphetamine (7395). | I | Heroin (9200) | I |
| 4-Methylaminorex (cis isomer) (1590). | I | Hydromorphanol (9301) | I |
| 4-Methoxyamphetamine (7411) ... | I | Hydroxypethidine (9627) | I |
| 5-Methoxy-3,4-methylenedioxyamphetamine (7401). | I | Ibogaine (7260) | I |
| 5-Methoxy-N,N-diisopropyltryptamine (7439). | I | Ketobemidone (9628) | I |
| Acetorphine (9319) | I | Levomoramide (9629) | I |
| Acetyl-alpha-methylfentanyl (9815). | I | Levophenacetyl morphan (9631) | I |
| Acetyldihydrocodeine (9051) | I | Lysergic acid diethylamide (7315) | I |
| Acetylmethadol (9601) | I | Marihuana (7360) | I |
| Allylprodine (9602) | I | Mecloqualone (2572) | I |
| Alphacetylmethadol except levo-alphacetylmethadol (9603). | I | Mescaline (7381) | I |
| Alpha-ethyltryptamine (7249) | I | Methaqualone (2565) | I |
| Alphameprodine (9604) | I | Methcathinone (1237) | I |
| Alphamethadol (9605) | I | Methyldesorphine (9302) | I |
| Alpha-methylfentanyl (9814) | I | Methyldihydromorphine (9304) | I |
| Alpha-methylthiofentanyl (9832) ... | I | Morpheridine (9632) | I |
| Alpha-methyltryptamine (7432) ... | I | Morphine methylbromide (9305) .. | I |
| Aminorex (1585) | I | Morphine methylsulfonate (9306) | I |
| Benzethidine (9606) | I | Morphine-N-Oxide (9307) | I |
| Benzylmorphine (9052) | I | Myrophine (9308) | I |
| Betacetylmethadol (9607) | I | N,N-Dimethylamphetamine (1480) | I |
| Beta-hydroxy-3-methylfentanyl (9831). | I | N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (9834). | I |
| Beta-hydroxyfentanyl (9830) | I | N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (9818). | I |
| Betameprodine (9608) | I | N-Benzylpiperazine (7493) | I |
| Betamethadol (9609) | I | N-Ethyl-3-piperidyl benzilate (7482). | I |
| Betaprodine (9611) | I | N-Ethylamphetamine (1475) | I |
| Bufotenine (7433) | I | N-Ethyl-1-phenylcyclohexylamine (7455). | I |
| Cathinone (1235) | I | N-Hydroxy-3,4-methylenedioxyamphetamine (7402). | I |
| Clonitazene (9612) | I | Nicocodeine (9309) | I |
| Codeine methylbromide (9070) | I | Nicomorphine (9312) | I |
| Codeine-N-Oxide (9053) | I | N-Methyl-3-piperidyl benzilate (7484). | I |
| Cyprenorphine (9054) | I | Noracymethadol (9633) | I |
| Desomorphine (9055) | I | Norlevorphanol (9634) | I |
| Dextromoramide (9613) | I | Normethadone (9635) | I |
| Diampromide (9615) | I | Normorphine (9313) | I |
| Diethylthiambutene (9616) | I | Norpipanone (9636) | I |
| Diethyltryptamine (7434) | I | Para-Fluorofentanyl (9812) | I |
| Difenoxin (9168) | I | Parahexyl (7374) | I |
| Dihydromorphine (9145) | I | Peyote (7415) | I |
| Dimenoxadol (9617) | I | Phenadoxone (9637) | I |
| Dimepheptanol (9618) | I | Phenampromide (9638) | I |
| | | Phenomorphane (9647) | I |
| | | Phenoperidine (9641) | I |
| | | Pholcodine (9314) | I |
| | | Piritramide (9642) | I |
| | | Proheptazine (9643) | I |
| | | Propidine (9644) | I |
| | | Propiram (9649) | I |
| | | Psilocybin (7437) | I |
| | | Psilocyn (7438) | I |
| | | Racemoramide (9645) | I |
| | | Tetrahydrocannabinols (7370) | I |
| | | Thebacon (9315) | I |
| | | Thiofentanyl (9835) | I |

| Drug | Schedule |
|---|----------|
| Tilidine (9750) | I |
| Trimeperidine (9646) | I |
| 1-Phencyclohexylamine (7460) | II |
| 1- Piperidinocyclohexanecarbonitrile (8603). | II |
| Alfentanil (9737) | II |
| Alphaprodine (9010) | II |
| Amobarbital (2125) | II |
| Amphetamine (1100) | II |
| Anileridine (9020) | II |
| Beztramide (9800) | II |
| Carfentanil (9743) | II |
| Coca Leaves (9040) | II |
| Cocaine (9041) | II |
| Codeine (9050) | II |
| Dextropropoxyphene, bulk (non-dosage forms) (9273). | II |
| Dihydrocodeine (9120) | II |
| Dihydroetorphine (9334) | II |
| Diphenoxylate (9170) | II |
| Ethylmorphine (9190) | II |
| Etorphine Hcl (9059) | II |
| Fentanyl (9801) | II |
| Glutethimide (2550) | II |
| Hydrocodone (9193) | II |
| Hydromorphone (9150) | II |
| Isomethadone (9226) | II |
| Levo-alphaacetylmetadol (9648) .. | II |
| Levomethorphan (9210) | II |
| Levorphanol (9220) | II |
| Lisdexamfetamine (1205) | II |
| Meperidine (9230) | II |
| Meperidine intermediate-A (9232) | II |
| Meperidine intermediate-B (9233) | II |
| Meperidine intermediate-C (9234) | II |
| Metazocine (9240) | II |
| Methadone (9250) | II |
| Methadone intermediate (9254) ... | II |
| Methamphetamine (1105) | II |
| Methylphenidate (1724) | II |
| Metopon (9260) | II |
| Moramide intermediate (9802) | II |
| Morphine (9300) | II |
| Nabilone (7379) | II |
| Opium, raw (9600) | II |
| Opium extracts (9610) | II |
| Opium fluid extract (9620) | II |
| Opium tincture (9630) | II |
| Opium, granulated (9640) | II |
| Oxycodone (9143) | II |
| Oxymorphone (9652) | II |
| Pentobarbital (2270) | II |
| Phenazocine (9715) | II |
| Phencyclidine (7471) | II |
| Phenmetrazine (1631) | II |
| Phenylacetone (8501) | II |
| Piminodine (9730) | II |
| Powdered opium (9639) | II |
| Racemethorphan (9732) | II |
| Racemorphan (9733) | II |
| Remifentanil (9739) | II |
| Secobarbital (2315) | II |
| Sufentanil (9740) | II |
| Thebaine (9333) | II |

The company plans to import small quantities of the listed controlled substances for the National Institute on Drug Abuse (NIDA) for research activities.

No comments or objections have been received. DEA has considered the

factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Research Triangle Institute to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Research Triangle Institute to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
 [FR Doc. E9-21534 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 21, 2009, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II.

The company plans to manufacture small quantities of the above listed controlled substance for distribution to its customers for the purpose of research.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrissette Drive,

Springfield, Virginia 22152; and must be filed no later than November 9, 2009.

Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
 [FR Doc. E9-21521 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 8, 2009, Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

| Drug | Schedule |
|------------------------------|----------|
| Dihydrocodeine (9145) | I |
| Amphetamine (1100) | II |
| Methamphetamine (1105) | II |
| Amobarbital (2125) | II |
| Pentobarbital (2270) | II |
| Secobarbital (2315) | II |
| Phenylacetone (8501) | II |
| Cocaine (9041) | II |
| Codeine (9050) | II |
| Dihydrocodeine (9120) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Diphenoxylate (9170) | II |
| Ecgonine (9180) | II |
| Hydrocodone (9193) | II |
| Meperidine (9230) | II |
| Methadone (9250) | II |
| Morphine (9300) | II |
| Oxymorphone (9652) | II |
| Alfentanil (9737) | II |
| Remifentanil (9739) | II |
| Sufentanil (9740) | II |
| Fentanyl (9801) | II |

The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 9, 2009.